Carlos Daniel Rose

Carlos Daniel Rose, a minority-owned and Hispanic American-owned sole proprietorship based in Chadds Ford, Pennsylvania, provides medical expert services to the federal government as a prime contractor, specializing in vaccine injury claim evaluation and expert witness testimony under total small business set-asides and full-and-open competitions. Rose operates exclusively as a medical expert service provider, with no subcontract footprint across his federal portfolio.

Rose's customer base is highly concentrated. The Department of Health and Human Services, Health Resources and Services Administration Headquarters accounts for 223 of 231 awards (98% of recent awards) valued at $21.9 million combined potential value, anchored entirely to the Vaccine Injury Compensation Program. The Department of Justice Civil Division represents the remaining customer, with 3 awards valued at $27 thousand for expert witness services. This concentration reflects Rose's specialized niche: medical case review, medical record analysis, written evaluations, and expert testimony supporting adjudication of vaccine injury claims under the VICP's no-fault compensation framework.

Rose holds a $7.5 million single-award Blanket Purchase Agreement with HRSA running through July 2029 (awarded July 2024), the primary vehicle for recent work. Four additional BPAs with lower ceilings ($249 thousand to $7.5 million ranges, according to award summaries) issued between 2019 and 2024 generated the bulk of historical task orders. The top four vehicles by task-order count—BPA HHSH234200851016B (67 task orders, $229 thousand), BPA HHSH250201400062B (63 task orders, $195 thousand), BPA 75R60221A00005 (51 task orders, $313 thousand), and BPA 75R60219A00081 (41 task orders, $108 thousand)—represent cyclical VICP case work issued as individual BPA calls ranging from $1,500 to $37,500 per call.

Activity has declined markedly. Rose received 11 awards in 2022 and 16 in 2023, contracting to 8 in 2024, 6 in 2025, and 2 so far in 2026. Only 2 awards ($47 thousand combined potential value) face recompete completion within the next twenty-four months, signaling minimal near-term exposure; however, the trajectory suggests work volume pressure, likely driven by the 2024 award of the new $7.5 million HRSA BPA consolidating prior fragmented BPA vehicles into a single larger ceiling. Obligated dollars total $866 thousand against $21.9 million in combined potential value (4% utilization), indicating the majority of awarded ceiling remains unexercised.

Rose's categorization reflects his specialization: 229 of 231 awards fall under NAICS 621111 (Offices of Physicians except Mental Health Specialists), with 223 awards coded to PSC Support-Professional Expert Witness. His service model is pure expert consulting—medical evaluation and testimony on vaccine injury claims—with no prime-sub relationships and no government contracting or IT delivery capability extension. The portfolio demonstrates two decades of consistent, deep specialization in a single federal program (VICP work dating from 2007 in source records), with all prime award capture under small business set-asides or non-set-aside VICP-specific vehicles.